Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Next Previous
X
Search
Trial Profile

An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liprotamase (Primary)
  • Indications Exocrine pancreatic insufficiency
  • Focus Adverse reactions
  • Acronyms EASY
  • Sponsors Anthera Pharmaceuticals

    • Most Recent Events

    • 12 Mar 2018 According to an Anthera Pharmaceuticals media release, based on the data from RESULT trial the company is discontinuing further clinical development of Sollpura including the 20-Week Extension Period of RESULT, the SIMPLICITY study and the EASY study.
    • 12 Mar 2018 Status changed from recruiting to discontinued, as reported in an Anthera Pharmaceuticals Media Release.
    • 02 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top